Published online Dec 15, 2022. doi: 10.4251/wjgo.v14.i12.2367
Peer-review started: August 1, 2022
First decision: August 21, 2022
Revised: August 29, 2022
Accepted: November 16, 2022
Article in press: November 16, 2022
Published online: December 15, 2022
Processing time: 132 Days and 20.5 Hours
Liver cancer is a malignant tumor with high morbidity and mortality. One of the main reasons is that conventional Transcatheter arterial chemoembolization (TACE) is not a standardized procedure, and there are some differences in the use of embolization materials, selection of chemotherapeutic drugs, and operation techniques among different regions and teams.
This study compared the effect of using the same size of embolization particles and drug-eluting bead (DEB) during TACE. We investigated the effect and systemic response of chemotherapy drugs in TACE under the new local drug delivery mode.
This study aimed to explore the short-term efficacy of drug-loaded microspheres TACE (D-TACE) and traditional TACE in the treatment of advanced liver cancer.
The clinical data of 73 patients with advanced liver cancer admitted to the First and Sixth Medical Centers of Chinese PLA General Hospital from January 2017 to October 2019 were retrospectively analyzed.
There were no statistical differences in the values of glutamic oxalyl transaminase, glutamic alanine transaminase, total bilirubin, serum albumin, leukocytes, red blood cells, and platelets before and after surgery in the drug-laden microsphere group and the conventional TACE group. In the postoperative 24 h postoperative nausea and vomiting score and postoperative pain score, the traditional TACE group was higher than the drug-loaded microsphere group, and the data of the two groups were statistically different.
The authors found that compared with traditional TACE, D-TACE may have more advantages in the short-term efficacy for treating large hepatocellular carcinoma in the middle and late stages.
D-TACE is worthy of clinical promotion. However, the long-term prognosis of D-TACE and traditional TACE for patients with advanced liver cancer needs to be further explored in large-sample randomized controlled trials.